中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 4
Apr.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(4): 768-772

Association between sarcopenia and abnormal lipid metabolism in patients with liver cirrhosis and the potential benefits of transjugular intrahepatic portosystemic shunt

DOI: 10.12449/JCH250425

  • Department of Gastroenterology，The Second Affiliated Hospital of Kunming Medical University，Kunming 650033，China

Research funding:

National Natural Science Foundation of China (82360108);

Yunnan Leading Medical Talent Project (L-2019013)

More Information
  • Corresponding author: TANG Yingmei， tangyingmei_med@kmmu.edu.cn （ORCID： 0000-0002-0731-4198）
  • Received Date: 2024-07-28
  • Accepted Date: 2024-08-13
  • Published Date: 2025-04-25
    Abstract
  • With the progression of liver cirrhosis， patients often develop sarcopenia and lipid metabolism disorders， and the complex interaction between p sarcopenia and lipid metabolism disorders not only promotes the progression of liver cirrhosis， but also affects the prognosis and quality of life of patients. As an effective intervention for alleviating complications associated with liver cirrhosis， transjugular intrahepatic portosystemic shunt （TIPS） can improve sarcopenia to a certain degree by improving hepatic hemodynamics and reducing portal venous pressure. In addition， there might be varying degrees of changes in blood lipid levels after TIPS， which may be closely associated with the recovery of liver metabolic function and the alterations in hemodynamics. This article introduces the association between liver cirrhosis， sarcopenia， and lipid metabolism disorders， elaborates on the effect of TIPS on sarcopenia and abnormal lipid metabolism， and discusses related mechanism and clinical significance， in order to provide a theoretical basis for clinical treatment.

     

    • FullText(HTML)
  • loading
    • References(45)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408- 2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [2]
    DUDOV TR, SARITHALA VJ, KOROY PV, et al. Relationship between disorders of lipid profile and features of liver cirrhosis- an open prospective and comparative analysis of patients of stavropol territory in Russian federation[J]. J Clin Diagn Res, 2022, 16( 6):OC04-OC 10. DOI: 10.7860/jcdr/2022/53485.16426.
    [3]
    KIKUCHI N, UOJIMA H, HIDAKA H, et al. Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology[J]. Hepatol Res, 2021, 51( 9): 968- 978. DOI: 10.1111/hepr.13698.
    [4]
    MAJEED T, SHARMA B, SHARMA R, et al. Sarcopenia in cirrhosis: Unraveling the prevalence and relationships with liver disease severity and complications[J]. Indian J Gastroenterol, 2024, 43( 4): 813- 820. DOI: 10.1007/s12664-024-01550-0.
    [5]
    TOPAN MM, SPOREA I, DĂNILĂ M, et al. Impact of sarcopenia on survival and clinical outcomes in patients with liver cirrhosis[J]. Front Nutr, 2021, 8: 766451. DOI: 10.3389/fnut.2021.766451.
    [6]
    TANTAI XX, LIU Y, YEO YH, et al. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis[J]. J Hepatol, 2022, 76( 3): 588- 599. DOI: 10.1016/j.jhep.2021.11.006.
    [7]
    FENG RR, GUO XZ, KOU Y, et al. Association of lipid profile with decompensation, liver dysfunction, and mortality in patients with liver cirrhosis[J]. Postgrad Med, 2021, 133( 6): 626- 638. DOI: 10.1080/00325481.2021.1930560.
    [8]
    DHALIWAL A, ARMSTRONG MJ. Sarcopenia in cirrhosis: A practical overview[J]. Clin Med(Lond), 2020, 20( 5): 489- 492. DOI: 10.7861/clinmed.2020-0089.
    [9]
    KUMAR R, PRAKASH SS, PRIYADARSHI RN, et al. Sarcopenia in chronic liver disease: A metabolic perspective[J]. J Clin Transl Hepatol, 2022, 10( 6): 1213- 1222. DOI: 10.14218/JCTH.2022.00239.
    [10]
    TRAUB J, REISS L, ALIWA B, et al. Malnutrition in patients with liver cirrhosis[J]. Nutrients, 2021, 13( 2): 540. DOI: 10.3390/nu13020540.
    [11]
    REN XJ, HAO SS, YANG CL, et al. Alterations of intestinal microbiota in liver cirrhosis with muscle wasting[J]. Nutrition, 2021, 83: 111081. DOI: 10.1016/j.nut.2020.111081.
    [12]
    JIANG HL, PENG Y, ZHANG W, et al. Gut microbiome-targeted therapies in liver cirrhosis: A protocol for systematic review and meta-analysis[J]. Syst Rev, 2022, 11( 1): 181. DOI: 10.1186/s13643-022-02059-3.
    [13]
    XU JQ, PAN YK, ZHANG JX, et al. Sarcopenia in liver cirrhosis: Perspectives from epigenetics and microbiota[J]. Front Med(Lausanne), 2023, 10: 1264205. DOI: 10.3389/fmed.2023.1264205.
    [14]
    IACOB S, MINA V, MANDEA M, et al. Assessment of sarcopenia related quality of life using SarQoL® questionnaire in patients with liver cirrhosis[J]. Front Nutr, 2022, 9: 774044. DOI: 10.3389/fnut.2022.774044.
    [15]
    DING HR, WANG JL, REN HZ, et al. Lipometabolism and glycometabolism in liver diseases[J]. Biomed Res Int, 2018, 2018: 1287127. DOI: 10.1155/2018/1287127.
    [16]
    KANO N, WANT EJ, MCPHAIL MJW. Metabolomics in advanced liver disease[J]. Curr Treat Options Gastroenterol, 2021, 19( 2): 380- 397. DOI: 10.1007/s11938-021-00347-w.
    [17]
    YAMUNA J, AKILA A, MURUGANANDAM VU, et al. Lipid profile as an indicator of severity in cirrhosis of liver: Hospital based cross-sectional study[J]. J Assoc Physicians India, 2023, 71( 3): 11- 12. DOI: 10.5005/japi-11001-0210.
    [18]
    SHI CC, LIU YJ, ZHANG RN, et al. Dyslipidemia in patients with liver cirrhosis[J]. Prac Hepatol, 2021, 24( 6): 859- 862. DOI: 10.3969/j.issn.1672-5069.2021.06.023.

    石翠翠, 刘彦君, 章瑞南, 等. 肝硬化患者血脂异常分析[J]. 实用肝脏病杂志, 2021, 24( 6): 859- 862. DOI: 10.3969/j.issn.1672-5069.2021.06.023.
    [19]
    HOVE M TEN, PATER L, STORM G, et al. The hepatic lipidome: From basic science to clinical translation[J]. Adv Drug Deliv Rev, 2020, 159: 180- 197. DOI: 10.1016/j.addr.2020.06.027.
    [20]
    KIM H, PARK C, KIM TH. Targeting liver X receptors for the treatment of non-alcoholic fatty liver disease[J]. Cells, 2023, 12( 9): 1292. DOI: 10.3390/cells12091292.
    [21]
    CLÀRIA J, CURTO A, MOREAU R, et al. Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis[J]. J Hepatol, 2021, 75( 5): 1116- 1127. DOI: 10.1016/j.jhep.2021.06.043.
    [22]
    SHOAIB N, KHAN Z, IBRAHIM M, et al. Dyslipidemia and impaired liver function biomarkers in patients with hepatitis B liver cirrhosis[J]. J Taibah Univ Med Sci, 2023, 18( 4): 748- 754. DOI: 10.1016/j.jtumed.2023.01.002.
    [23]
    CHEN WQ, FANG Y, WANG WL, et al. Relationships between upper gastrointestinal bleeding,blood lipid level and Hp infection in cirrhosis patients[J]. J Trop Med, 2023, 23( 3): 360- 363, 429. DOI: 10.3969/j.issn.1672-3619.2023.03.017.

    陈凤琴, 方园, 王万亮, 等. 肝硬化患者上消化道出血与血脂水平及Hp感染的关系[J]. 热带医学杂志, 2023, 23( 3): 360- 363, 429. DOI: 10.3969/j.issn.1672-3619.2023.03.017.
    [24]
    GIOIA S, RIDOLA L, CRISTOFARO L, et al. The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt[J]. Liver Int, 2021, 41( 12): 2965- 2973. DOI: 10.1111/liv.15060.
    [25]
    SAEDI A AL, DEBRUIN DA, HAYES A, et al. Lipid metabolism in sarcopenia[J]. Bone, 2022, 164: 116539. DOI: 10.1016/j.bone.2022.116539.
    [26]
    HAN YQ, SUN QW, CHEN W, et al. New advances of adiponectin in regulating obesity and related metabolic syndromes[J]. J Pharm Anal, 2024, 14( 5): 100913. DOI: 10.1016/j.jpha.2023.12.003.
    [27]
    CHOI KM. The impact of organokines on insulin resistance, inflammation, and atherosclerosis[J]. Endocrinol Metab(Seoul), 2016, 31( 1): 1- 6. DOI: 10.3803/EnM.2016.31.1.1.
    [28]
    LIU CR, CHENG KY, TONG X, et al. The role of obesity in sarcopenia and the optimal body composition to prevent against sarcopenia and obesity[J]. Front Endocrinol(Lausanne), 2023, 14: 1077255. DOI: 10.3389/fendo.2023.1077255.
    [29]
    KARLSEN A, MACKEY AL, SUETTA C, et al. What is the impact of acute inflammation on muscle performance in geriatric patients?[J]. Exp Gerontol, 2020, 138: 111008. DOI: 10.1016/j.exger.2020.111008.
    [30]
    LI CW, YU K, SHYH-CHANG N, et al. Pathogenesis of sarcopenia and the relationship with fat mass: Descriptive review[J]. J Cachexia Sarcopenia Muscle, 2022, 13( 2): 781- 794. DOI: 10.1002/jcsm.12901.
    [31]
    YAMAMOTO S, HONMA K, FUJII M, et al. SHRSP5/Dmcr rats fed a high-fat and high-cholesterol diet develop disease-induced sarcopenia as nonalcoholic steatohepatitis progresses[J]. Ann Anat, 2023, 249: 152104. DOI: 10.1016/j.aanat.2023.152104.
    [32]
    LIN WM, SONG HB, SHEN JQ, et al. Functional role of skeletal muscle-derived interleukin-6 and its effects on lipid metabolism[J]. Front Physiol, 2023, 14: 1110926. DOI: 10.3389/fphys.2023.1110926.
    [33]
    RYU H, JEONG HH, LEE S, et al. LPS-induced modifications in macrophage transcript and secretion profiles are linked to muscle wasting and glucose intolerance[J]. J Microbiol Biotechnol, 2024, 34( 2): 270- 279. DOI: 10.4014/jmb.2309.09037.
    [34]
    WANG M, YANG ZH, ZHAI HM. Association of high-density lipoprotein cholesterol with sarcopenia in Chinese community-dwelling middle-aged and older adults: Evidence from 4-year longitudinal study[J]. Gerontology, 2024, 70( 8): 812- 822. DOI: 10.1159/000538980.
    [35]
    GHZAIEL I, ZARROUK A, PIRES V, et al. 7β-hydroxycholesterol and 7-ketocholesterol: New oxidative stress biomarkers of sarcopenia inducing cytotoxic effects on myoblasts and myotubes[J]. J Steroid Biochem Mol Biol, 2023, 232: 106345. DOI: 10.1016/j.jsbmb.2023.106345.
    [36]
    MCCULLOUGH D, WEBB R, ENRIGHT KJ, et al. How the love of muscle can break a heart: Impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health[J]. Rev Endocr Metab Disord, 2021, 22( 2): 389- 405. DOI: 10.1007/s11154-020-09616-y.
    [37]
    WANG CY, HE FL, WANG Y. North American Practice-Based Recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension[J]. J Prac Hepatol, 2022, 25( 4): 609- 610. DOI: 10.3969/j.issn.1672-5069.2022.04.039.

    汪春雨, 何福亮, 王宇. 经颈静脉肝内门体静脉分流术临床实践指南推荐意见[J]. 实用肝脏病杂志, 2022, 25( 4): 609- 610. DOI: 10.3969/j.issn.1672-5069.2022.04.039.
    [38]
    GIRI S, ANIRVAN P, CHAUDHARY M, et al. Impact of nutritional status on the outcome of transjugular intrahepatic portosystemic shunt in patients with cirrhosis: A systematic review[J]. Br J Radiol, 2024, 97( 1154): 331- 340. DOI: 10.1093/bjr/tqad065.
    [39]
    ARTRU F, MIQUET X, AZAHAF M, et al. Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: A large retrospective CT-based surveillance[J]. Aliment Pharmacol Ther, 2020, 52( 9): 1516- 1526. DOI: 10.1111/apt.16080.
    [40]
    XIONG B, YANG CT. Association between transjugular intrahepatic portosystemic shunt and sarcopenia in patients with liver cirrhosis[J]. J Clin Hepatol, 2023, 39( 7): 1541- 1546. DOI: 10.3969/j.issn.1001-5256.2023.07.005.

    熊斌, 杨崇图. 肝硬化患者经颈静脉肝内门体分流术与肝硬化肌少症的关系[J]. 临床肝胆病杂志, 2023, 39( 7): 1541- 1546. DOI: 10.3969/j.issn.1001-5256.2023.07.005.
    [41]
    CURRIE BM, BAKHTIAR M, NADOLSKI GJ, et al. Mitigation of sarcopenia after peritoneovenous shunt placement in patients with refractory ascites[J]. J Vasc Interv Radiol, 2023, 34( 4): 633- 638. DOI: 10.1016/j.jvir.2022.12.037.
    [42]
    AHMED Z, BADAL J, GANGWANI MK, et al. Sarcopenia is a risk factor for post-transjugular intrahepatic portosystemic shunt hepatic encephalopathy and mortality: A systematic review and meta-analysis[J]. Indian J Gastroenterol, 2024, 43( 4): 748- 759. DOI: 10.1007/s12664-023-01465-2.
    [43]
    LIU JC, MA JQ, YANG CT, et al. Sarcopenia in patients with cirrhosis after transjugular intrahepatic portosystemic shunt placement[J]. Radiology, 2022, 303( 3): 711- 719. DOI: 10.1148/radiol.211172.
    [44]
    DELGADO MG, MERTINEIT N, BOSCH J, et al. Combination of Model for End-Stage Liver Disease(MELD) and Sarcopenia predicts mortality after transjugular intrahepatic portosystemic shunt(TIPS)[J]. Dig Liver Dis, 2024, 56( 9): 1544- 1550. DOI: 10.1016/j.dld.2024.03.003.
    [45]
    BALLESTER MP, LLUCH P, TOSCA J, et al. Serum cholesterol predicts transplant-free survival in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt[J]. Dig Liver Dis, 2021, 53( 12): 1596- 1602. DOI: 10.1016/j.dld.2021.04.035.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (509) PDF downloads(33) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return